Subtraction Analysis of Trabecular Meshwork Genes
About the Research Project
Program
Award Type
Standard
Award Amount
$70,000
Active Dates
April 01, 2002 - March 31, 2004
Grant ID
G2002025
Summary
Dr. Tamm has previously identified three genes, pax-6, uteroglobulin and thrombospondin-1 that are differentially expressed in a murine trabecular meshwork (TM) cell line under differentiating or non-differentiating conditions. The goal of this proposal is to examine the role of these three genes in glaucoma with the use of various knockout mice. It is hypothesized that pax-6 is the major control gene for TM development. Dr. Tamm is working to determine if pax-6 acts directly on the development of the TM or indirectly via its induction of other factors in lens, iris/ciliary epithelium or retina. He also hopes to determine if a deficiency or lack of uteroglobulin expression leads to morphological and functional changes in the anterior eye segment and TM, comparable to that seen in glaucoma associated with pigment dispersion syndrome. He is also examining thrombospondin-1 expression in the regulation of TGF-beta and TGF-beta controlled genes. Thrombospondin-1 is expressed in the TM and is an activator of TGF-beta, which is found at high levels in the aqueous humor of eyes with primary open-angle glaucoma (POAG). He will analyze the TM phenotype in mice lacking the expression of thrombospondin-1. It is hoped that the proposed studies will lead to a better understanding of the etiology of both congenital glaucoma and POAG by better understanding the molecular biology of the TM, the specialized tissue through which the aqueous fluid drains. This project is a continuation of a study by the same name, begun in 2000.
Related Grants
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester